The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Hypertension
Initial dose: 10 mg orally once a day in patients not on diuretics
Maintenance dose: 20 to 80 mg/day orally, given in 1 to 2 divided doses
Renal Dose Adjustments
CrCl 30 to 60 mL/min:
Initial dose: 5 mg orally once a day
CrCl 10 to 30 mL/min:
Initial dose: 2.5 mg orally once a day
Liver Dose Adjustments
Data not available
Antihypertensive doses should be adjusted according to blood pressure response measured at peak (2-6 hours after dosing) and trough (predosing). Generally, dosage adjustments should be made at intervals of at least 2 weeks.
In some patients treated once daily, the antihypertensive effect may diminish toward the end of the dosing interval. In such patients an increase in dosage or twice daily administration may be warranted. In general, doses of 40-80 mg and divided doses give a somewhat greater effect at the end of the dosing interval.
Heart Failure doses should be titrated at weekly intervals until an effective dose is reached or undesirable hypotension, orthostasis, or azotemia prohibit reaching this dose.
Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).
Quinapril is not removed by hemo- or peritoneal dialysis.
If blood pressure is not adequately controlled with quinapril monotherapy, a diuretic may be added.
Quinapril is indicated as adjunctive therapy for treating heart failure when added to conventional therapy including diuretics and/or digitalis.
Compared with Caucasian patients, Black patients have a reduced blood pressure response to monotherapy with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers; however, the reduced response is largely eliminated if combination therapy that includes an adequate dose of a diuretic is instituted.
Following first time MI, all ACE inhibitors, at comparable appropriate dosages, appear to be equally effective for reducing mortality and recurrent MI rates.
More about quinapril
- Other brands: Accupril